RESUMEN
Background/Objectives: Atrial fibrillation (AF) and flutter (AFL) are the most common cardiac arrhythmias worldwide. Cardiovascular complications are a common manifestation of acute and post-acute COVID-19 infection. We aimed to analyze the nationwide trends in clinical characteristics and outcomes of patients hospitalized for AF/AFL before and during the COVID-19 outbreak in the U.S. Methods: This study is a retrospective analysis of patients, aged 18 and older, hospitalized for AF/AFL in the U.S. between 2016 and 2020. We drew data from the National Inpatient Sample (NIS) database. Baseline sociodemographic and clinical data, as well as outcomes including stroke, acute coronary syndrome (ACS), and mortality, were analyzed. Multivariable analysis was performed to identify independent associations between the different clinical and demographic characteristics and the composite endpoint of Mortality/ACS/Stroke. Results: An estimated total of 2,163,699 hospitalizations for AF/AFL were identified. The hospitalization volume between 2016 and 2019 was stable, averaging 465,176 a year, followed by a significant drop to 302,995 in 2020. Patients' median age was 72 years (IQR 62-80), 50.9% were male, and 81.5% were white. The composite endpoint steadily increased from 6.5% in 2016 to 11.8% in 2020 (Ptrend < 0.001). In a multivariable regression analysis, age > 75 (OR: 1.35; 95% CI 1.304-1.399, p < 0.001), ischemic heart disease (OR: 1.466; 95% CI: 1.451-1.481; p < 0.001), and chronic kidney disease (OR: 1.635; 95% CI: 1.616-1.653; p < 0.001) were associated with the composite endpoint. COVID-19 was associated with the composite endpoint outcome in the year 2020 (OR: 1.147; 95% CI: 1.037-1.265; p = 0.007). Conclusions: Hospitalization for AF/AFL dropped significantly during the first year of the COVID-19 pandemic outbreak, possibly due to patients' avoidance of hospital visits. The composite endpoint of Mortality/ACS/Stroke uptrended significantly during the study period. COVID-19 was shown to be independently associated with the adverse composite outcome Mortality/ACS/Stroke.
RESUMEN
Background Routine addition of an atrial lead during an implantable cardioverter-defibrillator (ICD) implantation for primary prevention of sudden cardiac death, in patients without pacing indications, was not shown beneficial in contemporary studies. We aimed to investigate the use and safety of single- versus dual-chamber ICD implantations in these patients. Methods and Results Using the National Inpatient Sample database, we identified patients with no pacing indications who underwent primary-prevention ICD implantation in the United States between 2015 and 2019. Sociodemographic and clinical characteristics, as well as in-hospital complications, were analyzed. Multivariable logistic regression was used to identify predictors of in-hospital complications. An estimated total of 15 940 patients, underwent ICD implantation for primary prevention of sudden cardiac death during the study period, 8860 (55.6%) received a dual-chamber ICD. The mean age was 64 years, and 66% were men. In-hospital complication rates in the dual-chamber ICD and single-chamber ICD group were 12.8% and 10.7%, respectively (P<0.001), driven by increased rates of pneumothorax/hemothorax (4.6% versus 3.4%; P<0.001) and lead dislodgement (3.6% versus 2.3%; P<0.001) in the dual-chamber ICD group. Multivariable analyses confirmed atrial lead addition as an independent predictor for "any complications" (odds ratio [OR], 1.1 [95% CI, 1.0-1.2]), for pneumo/hemothorax (odds ratio, 1.1 [95% CI, 1.0-1.4]), and for lead dislodgement (odds ratio, 1.3 [95% CI, 1.1-1.6]). Conclusions Despite lack of evidence for clinical benefit, dual-chamber ICDs are implanted for primary prevention of sudden cardiac death in a majority of patients who do not have pacing indication. This practice is associated with increased risk of periprocedural complications. Avoidance of routine implantation of atrial leads will likely improve safety outcomes.
Asunto(s)
Fibrilación Atrial , Desfibriladores Implantables , Masculino , Humanos , Estados Unidos/epidemiología , Persona de Mediana Edad , Femenino , Desfibriladores Implantables/efectos adversos , Fibrilación Atrial/etiología , Hemotórax/etiología , Muerte Súbita Cardíaca/epidemiología , Muerte Súbita Cardíaca/etiología , Muerte Súbita Cardíaca/prevención & control , Prevención Primaria/métodos , Sistema de RegistrosRESUMEN
The convergent procedure is a hybrid ablation treatment for atrial fibrillation. It is increasingly considered as a management option for patients with persistent and long-standing atrial fibrillation. It consists of surgical ablation of the posterior left atrium through a minimally invasive closed-chest approach followed by endocardial catheter ablation. It is increasingly performed with concurrent epicardial occlusion of the left atrial appendage with a video-assisted thoracoscopic technique to physically and electrically isolate the left atrial appendage. This article provides an overview of a multidisciplinary approach to the convergent procedure, with concurrent thoracoscopic closure of the left atrial appendage, with an emphasis on perioperative management at a single institution. It provides a literature review of procedural outcomes, current data limitations, and future considerations.
Asunto(s)
Fibrilación Atrial , Ablación por Catéter , Fibrilación Atrial/cirugía , Humanos , Recurrencia , Factores de Tiempo , Resultado del TratamientoRESUMEN
In the midst of the COVID-19 pandemic, we herein report the case of an elderly female with multiple comorbidities coming with typical symptoms of the viral infection in addition to the unusual presentation of bradycardia due to complete heart block requiring pacemaker placement. This may be a rare complication of the disease but one has to keep a high index of suspicion since this virus has an ability to affect multiple organ systems with many ways yet to be uncovered.
RESUMEN
His bundle pacing (HBP) has recently emerged as a technique to avoid the negative effects of long-term right ventricular apical pacing. In addition to providing physiologic ventricular activation, HBP has been shown to correct underlying conduction abnormalities in certain patients. Although large prospective, randomized clinical trials have not yet been completed, the available observational clinical data support the safety and efficacy of this technique. Here, we review the physiology of the his bundle (HB) as it relates to HBP, describe the current clinical experience, and discuss future directions of this emerging therapy.
Asunto(s)
Bloqueo Atrioventricular/prevención & control , Bloqueo de Rama/terapia , Estimulación Cardíaca Artificial/métodos , Electrocardiografía , Marcapaso Artificial , Fascículo Atrioventricular/fisiopatología , Bloqueo de Rama/diagnóstico por imagen , Cateterismo Cardíaco/métodos , Terapia de Resincronización Cardíaca/métodos , Femenino , Humanos , Masculino , Pronóstico , Medición de Riesgo , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Sudden death is a major problem, with significant impact on public health. Many conditions predispose to sudden cardiac death and sudden cardiac arrest (SCA), foremost among them coronary artery disease, and an effective therapy exists in the form of the implantable cardioverter defibrillator. Risk stratification for SCA remains imperfect, especially for patients with nonischemic cardiomyopathy. Ongoing trials may make it easier to identify those at high risk, and potentially those at very low risk, in the future.
Asunto(s)
Muerte Súbita Cardíaca , Arritmias Cardíacas , Muerte Súbita Cardíaca/epidemiología , Muerte Súbita Cardíaca/prevención & control , Humanos , Isquemia Miocárdica , Volumen SistólicoAsunto(s)
Arritmias Cardíacas , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/genética , Arritmias Cardíacas/terapia , Electrofisiología Cardíaca/métodos , Canalopatías/complicaciones , Canalopatías/genética , Muerte Súbita Cardíaca/etiología , Desfibriladores Implantables , Electrocardiografía , HumanosRESUMEN
Evidence-based medicine has provided the foundation for refinement of the guideline development process and the emergence of the disciplines of measuring quality, performance, and outcomes. With implementation of electronic medical records as part of healthcare reform, multiple aspects of these disciplines will be incorporated into clinical cardiac electrophysiology. Performance measures and quality metrics will assume an influential role in the management of patients with heart rhythm disturbances in the near future.
Asunto(s)
Arritmias Cardíacas/terapia , Cardiología/métodos , Cardiología/normas , Medicina Basada en la Evidencia/métodos , Medicina Basada en la Evidencia/normas , Desarrollo de Programa , Garantía de la Calidad de Atención de Salud , Anticoagulantes/uso terapéutico , Fibrilación Atrial/terapia , Ablación por Catéter , Humanos , Guías de Práctica Clínica como Asunto , Sistema de Registros , Resultado del TratamientoRESUMEN
Sudden death in the athlete is a rare occurrence, yet there is evidence that screening may reduce this tragedy. Pre-participation screening programs differ between the United States and Italy. The causes of sudden death in this young, athletic population are reviewed, as are each program's merits and pitfalls.